Global Anti-Emetic Drugs Market – Industry Trends and Forecast to 2030

Global Anti-Emetic Drugs Market, By Site of Action (D2 Receptors, 5HT-3 Receptors, MI Receptors, HI Receptors), Type (Prescription drugs, Over-the-counter (OTC) drugs), Indication (Chemotherapy, Motion Sickness, Gastroenteritis, Dizziness, Pregnancy, Food Poisoning, Others), Drug Class (Prokinetics, Serotonin Antagonists, Antimuscarinics, Antihistaminic, Neurokinin Antagonists, Others),  Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.

Anti-Emetic Drugs Market Analysis and Size

Antiemetic drugs are medications that assist prevent nausea, dizziness, and vomiting. Antiemetic drugs are used to treat a variety of disorders, including vertigo and motion sickness. Anti-emetics have a high volume market because most drugs have reached the end of their patent protection period. Despite scientific efforts to improve the efficacy of target site specificity, the anti-emetics business is mostly focused on generic medication development. The application of anti-emetics for oncological therapy is also being investigated. Antiemetic medications are required throughout chemotherapy-induced vomiting and the early stages of pregnancy. Antiemetic medications are also used to treat toxins, food poisoning, and the side effects of other drugs that cause nausea and vomiting.                                

Data Bridge Market Research analyses that the global anti-emetic drugs market which was USD 7,543.13 million in 2022, is expected to reach USD 12,840.23 million by 2030, and is expected to undergo a CAGR of 6.06% during the forecast period of 2023 to 2030. “D2 Receptors” dominates the site of action segment of the global anti-emetic drugs market due to rising demand of anti-emetic drugs. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Anti-emetics are medications that help the body block certain neurotransmitters. Motion sickness, vestibular disorder, pregnancy, panic, medications, migraine, and gastrointestinal pathology are all typical causes of vomiting and nausea, which can be quite distressing. Postoperative nausea and vomiting are one of the most common causes of patient unhappiness after anesthesia (PONV). For the treatment of nausea and vomiting, anti-emetics such as dopamine antagonists, anticholinergics, antihistamines, serotonin antagonists, and others are available.

Global Anti-Emetic Drugs Market Dynamics

Drivers

• Rising Prevalence of Cancer

The increasing number of patients suffering from cancer will fuel industry growth. The rise in cardiovascular disorders is propelling the industry forward. Cancer caused the deaths of approximately 9-10 million people each year. Breast and lung cancer are the two most common types, and their frequency has increased dramatically. Breast cancer claimed the lives of over 680,000 people worldwide in 2021, with 2.3 million cases diagnosed. Similarly, the prevalence of lung cancer is increasing as a result of the rising smoking trend. According to a study, smoking is responsible for 82 percent of lung cancer problems. Chemotherapy is one of the most common cancer treatments, and it often comes with nausea and vomiting as a side effect. Chemotherapy accounts for the majority of the worldwide antiemetic medication market's uses. This can be attributed to the rising use of chemotherapy.

• Increasing Investment for Healthcare Infrastructure

Another significant factor influencing the growth rate of anti-emetic drugs market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aim to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics. Furthermore, surging geriatric population and rise in the number of government initiatives to spread awareness will result in the expansion of anti-emetic drugs market. Along with this, the sedentary lifestyle of people and increasing level of disposable income will enhance the market's growth rate.

• Expanding Surgical Procedures

Surgical procedures, whether minor or major, often lead to post-operative nausea and vomiting (PONV). With surgical interventions becoming more advanced and increasingly common, there is a growing need for effective anti-emetic drugs to minimize the risk of PONV. This surge in surgical procedures has created substantial demand for anti-emetics in the market.

Opportunities

• Expanding into Developing Markets

The global expansion of healthcare services in developing markets represents a substantial opportunity for the Global Anti-Emetic Drugs Market. As access to healthcare improves in these regions, a growing patient population emerges that requires anti-emetic therapies. By expanding into these markets, pharmaceutical companies can tap into new revenue streams.

• Advent of Personalized Medicine

The advent of personalized medicine offers significant opportunities for tailoring anti-emetic treatment regimens to individual patient profiles. Genetic and molecular markers can be utilized to predict a patient's susceptibility to emesis, thereby guiding treatment decisions and making anti-emetic therapy more effective and personalized.

Restraints/Challenges

• Side Effects of Anti-Emetics

It's important to acknowledge that anti-emetic drugs themselves can have side effects. Common side effects may include drowsiness, dizziness, and constipation. These side effects can be limiting, especially for patients who require complex drug regimens. Patients and healthcare providers must weigh the benefits of anti-emetics against these potential drawbacks.

• Competition and Pricing Pressure

The global anti-emetic drugs market is highly competitive, with several pharmaceutical companies manufacturing various anti-emetic medications. The presence of multiple manufacturers often leads to pricing pressure. This competition can affect profit margins and hinder the development of novel drugs in the market.

This global anti-emetic drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global anti-emetic drugs market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In April 2022, Evoke Pharma, Inc., was granted new drug product exclusivity by the U.S. Food and Drug Administration (FDA) for Gimoti (metoclopramide) nasal spray. Evoke now has exclusive marketing privileges over three years from the initial date of approval under the Hatch-Waxman Act to protect the product from generic drug competition. Metoclopramide is a dopamine antagonist that is used as a potent antiemetic drug

Global Anti-Emetic Drugs Market Scope

The global anti-emetic drugs market is segmented on the basis of site of action, indication, drug class, type, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Site of Action

• D2 Receptors
• 5ht-3 Receptors
• Mi Receptors
• Hi Receptors

Indication

• Chemotherapy
• Motion Sickness
• Gastroenteritis
• Dizziness
• Pregnancy
• Food Poisoning
• Others

Drug Class

• Prokinetics
• Serotonin Antagonists
• Antimuscarinics
• Antihistaminic
• Neurokinin Antagonists
• Others

Type

• Prescription Drugs
• Over-The-Counter (OTC) Drugs

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Anti-Emetic Drugs Market Regional Analysis/Insights

The global anti-emetic drugs market is analyzed and market size insights and trends are provided by country, site of action, indication, drug class, type, route of administration, end-users and distribution channel as referenced above.

The countries covered in the global anti-emetic drugs market report are U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the global anti-emetic drugs market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period of 2023 to 2030, due of the increase in the expenditure for research and development proficiencies, increasing government’s initiatives and improved health care infrastructure in various countries.

Asia-Pacific on the other hand is projected to exhibit the highest growth rate in the global anti-emetic drugs market during the forecast period of 2023 to 2030 owing to the increasing government expenditure on the healthcare sector and rising technological advancements and initiatives by the government.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The global anti-emetic drugs market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global anti-emetic drugs market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global anti-emetic drugs market. The data is available for historic period 2010-2020.

Competitive Landscape and Global Anti-Emetic Drugs Market Share Analysis

The global anti-emetic drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global anti-emetic drugs market.

Some of the major players operating in the global anti-emetic drugs market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Hikma Pharmaceuticals PLC (U.K.)
• Dr. Reddy's Laboratories Ltd. (India)
• Fresenius Kabi AG (Germany)
• Aurobindo Pharma (India)
• Kyowa Kirin Co., Ltd. (Japan)
• Akorn, Incorporated (U.S.)
• Glenmark Pharmaceuticals Limited (India)
• WOCKHARDT (India)
• Cipla Inc. (U.S.)
• Lupin (India)